Browsing by Author "Makhema, Joseph"

Browsing by Author "Makhema, Joseph"

Sort by: Order: Results:

  • Atypical hepatitis B virus serology profile—hepatitis B surface antigen-positive/hepatitis B core antibody-negative—in hepatitis B virus/HIV coinfected individuals in Botswana 
    Phinius, Bonolo B.; Anderson, Motswedi; Mokomane, Margaret; Gobe, Irene; Choga, Wonderful T.; Ratsoma, Tsholofelo; Phakedi, Basetsana; Mpebe, Gorata; Ditshwanelo, Doreen; Musonda, Rosemary; Makhema, Joseph; Moyo, Sikhulile (MDPI, 2023-07)
    BACKGROUND : Hepatitis B core antibodies (anti-HBc) are a marker of hepatitis B virus (HBV) exposure; hence, a normal HBV serology profile is characterized by HBV surface antigen (HBsAg) and anti-HBc positivity. However, ...
  • Safety of AZD1222 COVID-19 vaccine and low Incidence of SARS-CoV-2 infection in Botswana following ChAdOx1(AZD1222) vaccination : a single-arm open-label interventional study – final study results 
    Makhema, Joseph; Shava, Emily; Izu, Alane; Gaolathe, Tendani; Kuate, Lesego; Walker, Adam; Carty, Lucy; Georgiou, Panayiotis; Kgathi, Coulson; Choga, Wonderful T.; Sekoto, Tumalano; Seonyatseng, Ngozana; Mogashoa, Tuelo; Maphorisa, Comfort N.; Mohammed, Terence; Ntalabgwe, Tshenolo; Frank, Tshepho T.; Matlhaku, Boitumelo; Diphoko, Ame; Phindela, Thandie; Kaunda, Agripa; Kgari, Poloko; Kanyakula, Thomas; Palalani, Gape; Phakedi, Isabella; Mmalane, Mompati; Taylor, Sylvia; Moyo, Sikhulile (Elsevier, 2024-03)
    OBJECTIVES : We report the final analysis of the single-arm open-label study evaluating the safety and COVID-19 incidence after AZD1222 vaccination in Botswana conducted between September 2021 and August 2022. METHODS : ...
  • Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition 
    Corey, Lawrence; Gilbert, Peter B.; Juraska, Michal; Montefiori, David C.; Morris, Lynn; Karuna, Shelly T.; Edupuganti, Srilatha; Mgodi, Nyaradzo M.; DeCamp, Allan C.; Rudnicki, Erika; Huang, Yunda; Gonzales, Pedro; Cabello, Robinson; Orrell, Catherine; Lama, Javier R.; Laher, Fatima; Lazarus, Erica M.; Sanchez, Jorge; Frank, Ian; Hinojosa, Juan; Sobieszczyk, Magdalena E.; Marshall, Kyle E.; Mukwekwerere, Pamela G.; Makhema, Joseph; Baden, Lindsey R.; Mullins, James I.; Williamson, Carolyn; Hural, John; McElrath, Juliana; Bentley, Carter; Takuva, Simbarashe G.; Lorenzo, Margarita M. Gomez; Burns, David N.; Espy, Nicole; Randhawa, April K.; Kochar, Nidhi; Piwowar‑Manning, Estelle; Donnell, Deborah J.; Sista, Nirupama; Andrew, Philip; Kublin, James G.; Gray, Glenda; Ledgerwood, Julie E.; Mascola, John R.; Cohen, Myron S. (Massachusetts Medical Society, 2021-03-18)
    BACKGROUND : Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS : We enrolled at-risk cisgender men and transgender persons in ...